Prothena Corporation plc (PRTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Prothena Corporation plc (PRTA) has a cash flow conversion efficiency ratio of -0.138x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.56 Million) by net assets ($294.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Prothena Corporation plc for the company's overall valuation and market capitalisation.
Prothena Corporation plc - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Prothena Corporation plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Prothena Corporation plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Prothena Corporation plc ranked by their cash flow conversion efficiency. Explore PRTA cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hankook Shell Oil
KO:002960
|
0.065x |
|
Consolidated Water Co Ltd
NASDAQ:CWCO
|
0.068x |
|
Taiwan Chinsan Electronic Industrial Co Ltd
TWO:8042
|
0.042x |
|
Iteos Therapeutics Inc
NASDAQ:ITOS
|
-0.086x |
|
Tongqinglou Dining Co Ltd
SHG:605108
|
N/A |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
0.038x |
|
Hind Rectifiers Limited
NSE:HIRECT
|
0.333x |
|
PetroVietnam Transportation Corp
VN:PVT
|
0.088x |
Annual Cash Flow Conversion Efficiency for Prothena Corporation plc (2010–2024)
The table below shows the annual cash flow conversion efficiency of Prothena Corporation plc from 2010 to 2024. View Prothena Corporation plc (PRTA) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $486.93 Million | $-150.05 Million | -0.308x | -29.19% |
| 2023-12-31 | $561.37 Million | $-133.91 Million | -0.239x | -36.35% |
| 2022-12-31 | $622.04 Million | $-108.82 Million | -0.175x | -188.04% |
| 2021-12-31 | $466.04 Million | $92.61 Million | 0.199x | +145.50% |
| 2020-12-31 | $184.01 Million | $-80.36 Million | -0.437x | -125.03% |
| 2019-12-31 | $272.92 Million | $-52.97 Million | -0.194x | -121.70% |
| 2018-12-31 | $323.00 Million | $-28.28 Million | -0.088x | +72.83% |
| 2017-12-31 | $407.19 Million | $-131.18 Million | -0.322x | -0.39% |
| 2016-12-31 | $365.40 Million | $-117.27 Million | -0.321x | -85.33% |
| 2015-12-31 | $360.67 Million | $-62.45 Million | -0.173x | -7249.70% |
| 2014-12-31 | $289.89 Million | $-683.00K | -0.002x | +98.73% |
| 2013-12-31 | $173.27 Million | $-32.10 Million | -0.185x | +44.31% |
| 2012-12-31 | $126.48 Million | $-42.07 Million | -0.333x | -110.87% |
| 2011-12-31 | $-6.44 Million | $-19.70 Million | 3.060x | +103.37% |
| 2010-12-31 | $100.00K | $-9.08 Million | -90.830x | -- |
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson… Read more